Cantor Fitzgerald began coverage on shares of Keros Therapeutics (NASDAQ:KROS – Get Free Report) in a report released on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating on the stock.
KROS has been the topic of a number of other research reports. Scotiabank started coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Bank of America cut their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Finally, Guggenheim started coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $89.11.
Check Out Our Latest Report on KROS
Keros Therapeutics Stock Performance
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The company had revenue of $0.04 million during the quarter. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.88 earnings per share for the current fiscal year.
Insider Buying and Selling at Keros Therapeutics
In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 22.90% of the company’s stock.
Hedge Funds Weigh In On Keros Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Keros Therapeutics in the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the second quarter valued at about $128,000. Ameritas Investment Partners Inc. grew its stake in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares in the last quarter. Finally, Quest Partners LLC grew its stake in shares of Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after acquiring an additional 4,789 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
- Five stocks we like better than Keros Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Texas Roadhouse Stock Steering for New Highs This Year
- Breakout Stocks: What They Are and How to Identify Them
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Invest in Insurance Companies: A GuideĀ
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.